Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. / Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Andersen, Niels S.; Pedersen, Lone B.; Jerkeman, Mats; Eriksson, Mikael; Nordstrom, Marie; Kimby, Eva; Boesen, Anne Marie; Kuittinen, Outi; Lauritzsen, Grete F.; Nilsson-Ehle, Herman; Ralfkiaer, Elisabeth; Åkerman, Måns; Ehinger, Mats; Sundstrom, Christer; Langholm, Ruth; Delabie, Jan; Karjalainen-Lindsberg, Marja-Liisa; Brown, Peter; Elonen, Erkki.

I: Blood, Vol. 112, Nr. 7, 2008, s. 2687-2693.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Geisler, CH, Kolstad, A, Laurell, A, Andersen, NS, Pedersen, LB, Jerkeman, M, Eriksson, M, Nordstrom, M, Kimby, E, Boesen, AM, Kuittinen, O, Lauritzsen, GF, Nilsson-Ehle, H, Ralfkiaer, E, Åkerman, M, Ehinger, M, Sundstrom, C, Langholm, R, Delabie, J, Karjalainen-Lindsberg, M-L, Brown, P & Elonen, E 2008, 'Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group', Blood, vol. 112, nr. 7, s. 2687-2693. https://doi.org/10.1182/blood-2008-03-147025

APA

CBE

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Åkerman M, Ehinger M, Sundstrom C, Langholm R, Delabie J, Karjalainen-Lindsberg M-L, Brown P, Elonen E. 2008. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 112(7):2687-2693. https://doi.org/10.1182/blood-2008-03-147025

MLA

Vancouver

Author

Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Andersen, Niels S. ; Pedersen, Lone B. ; Jerkeman, Mats ; Eriksson, Mikael ; Nordstrom, Marie ; Kimby, Eva ; Boesen, Anne Marie ; Kuittinen, Outi ; Lauritzsen, Grete F. ; Nilsson-Ehle, Herman ; Ralfkiaer, Elisabeth ; Åkerman, Måns ; Ehinger, Mats ; Sundstrom, Christer ; Langholm, Ruth ; Delabie, Jan ; Karjalainen-Lindsberg, Marja-Liisa ; Brown, Peter ; Elonen, Erkki. / Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. I: Blood. 2008 ; Vol. 112, Nr. 7. s. 2687-2693.

RIS

TY - JOUR

T1 - Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

AU - Geisler, Christian H.

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Andersen, Niels S.

AU - Pedersen, Lone B.

AU - Jerkeman, Mats

AU - Eriksson, Mikael

AU - Nordstrom, Marie

AU - Kimby, Eva

AU - Boesen, Anne Marie

AU - Kuittinen, Outi

AU - Lauritzsen, Grete F.

AU - Nilsson-Ehle, Herman

AU - Ralfkiaer, Elisabeth

AU - Åkerman, Måns

AU - Ehinger, Mats

AU - Sundstrom, Christer

AU - Langholm, Ruth

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Brown, Peter

AU - Elonen, Erkki

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)

PY - 2008

Y1 - 2008

N2 - Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + highdose cytarabine. Responders received highdose chemotherapy with BEAM or BEAC carmustine, etoposide, cytarabine, and melphalan/ cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL- 1 trial, the event- free, overall, and progression- free survival, the duration of molecular remission, and the proportion of PCR- negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression- free survival of MCL and perhaps cure. Registered at www. isrctn. org as # ISRCTN 87866680.

AB - Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + highdose cytarabine. Responders received highdose chemotherapy with BEAM or BEAC carmustine, etoposide, cytarabine, and melphalan/ cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL- 1 trial, the event- free, overall, and progression- free survival, the duration of molecular remission, and the proportion of PCR- negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression- free survival of MCL and perhaps cure. Registered at www. isrctn. org as # ISRCTN 87866680.

U2 - 10.1182/blood-2008-03-147025

DO - 10.1182/blood-2008-03-147025

M3 - Article

VL - 112

SP - 2687

EP - 2693

JO - Blood

T2 - Blood

JF - Blood

SN - 1528-0020

IS - 7

ER -